Amgen's Dazodalibep Hits Primary Endpoint in Phase 3 Sjögren's Disease Trial
- Dazodalibep is a CD40 ligand (CD40L) antagonist fusion protein that blocks a key costimulatory signal between T cells, B cells and antigen-presenting cells implicated in Sjögren's disease.
- The Phase 3 OASIZ 301 trial randomized about 621 adults with moderate-to-severe systemic Sjögren's disease (ESSDAI ≥5) to dazodalibep or placebo.
- The study met its primary endpoint, showing a statistically significant and clinically meaningful reduction in ESSDAI disease-activity scores at Week 48, with benefit emerging as early as Week 4.
- No imbalance in blood clots or opportunistic infections was reported, a closely watched safety signal for this drug class; a second Phase 3 trial, OASIZ 303, in patients with lower systemic disease activity is due to complete in Q4 2026.
💡 Points
No imbalance in blood clots or infections is the headline that matters most: CD40L antagonists carry a long history of thromboembolic failures, so this clean safety data de-risks the whole mechanism, not just Amgen's asset. It also finally validates the $27.8B Horizon buy, giving Amgen the first credible disease-modifying candidate in a zero-approved-therapy indication—with a second Phase 3 in a milder segment positioning it to own both ends of the severity spectrum.
Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand deal ↗